Sponsors (2)
The bill strengthens oversight, reporting, and inspection of compounding to reduce risks from large‑scale or unsafe compounded drugs—but it does so at the cost of reduced access for some patients who need customized formulations, added compliance burdens (especially for small compounders), and potential short‑term supply and fee impacts.
Patients (especially those using chronic therapies) will face lower risk of receiving contaminated, adulterated, or substandard compounded drugs because the bill limits large‑scale compounding of commercial products and expands reporting and inspection authorities.
Licensed pharmacists, physicians, hospitals, and regulators get clearer legal boundaries and standardized reporting/registration rules, reducing regulatory uncertainty and enabling more targeted oversight and enforcement.
Hospitals and health systems benefit from clearer registration and inspection rules for large compounding facilities, improving supply‑chain transparency and traceability of where higher‑volume compounded products come from.
Patients who need individualized compounded drugs (e.g., for allergies, special dosing, or niche needs) may face reduced access, longer waits, or inability to obtain customized formulations because of limits on producing copies of commercial products and new registration/inspection timing.
Independent compounding pharmacies and small providers may lose revenue and face higher compliance costs (reporting, registration, possible IT upgrades, and new fees), threatening small businesses that specialize in customized compounding.
Reporting requirements that force disclosure of product types and monthly volumes raise privacy and business‑competition concerns for compounders and could expose commercially sensitive data to the government.
Based on analysis of 5 sections of legislative text.
Sets monthly and annual limits and reporting for compounded copies of commercial drugs, establishes inspection/registration rules for high-volume outsourcing facilities, and lets HHS set an establishment fee to fund safety oversight.
Official title: Amend the Federal Food, Drug, and Cosmetic Act to further regulate compounding pharmacies and outsourcing facilities, and for other purposes.
Introduced February 5, 2026 by James E. Banks · Last progress February 5, 2026
Limits how often pharmacies and physicians may compound copies of commercially available drugs, requires annual reporting when compounds for out-of-state patients exceed a monthly threshold, tightens registration and inspection rules for high-volume outsourcing facilities, and lets the HHS Secretary set a base establishment fee to fund safety oversight. The bill changes definitions and numeric thresholds in the Food, Drug, and Cosmetic Act to narrow when compounded products are treated as exempt and to expand inspection and registration obligations for larger compounding operations.